The authors discuss how more efforts need to ensure the methods used to measure the “value” of new therapies include factors that reflect patient heterogeneity.
Amy Miller, PhD
Advertisement
Articles by Amy Miller, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Lipoprotein(a): An FAQ on Awareness, Risk, and Screening Gaps
2
$20 Billion National Strategy Aims to Close the Women's Health Gap
3
Gene Therapy for Wet AMD Near an Inflection Point: Arshad Khanani, MD
4
Senate Unveils Sweeping Bill to Reform 340B Drug Program
5